Data Sheet (Cat.No.T22506)



3,4-DAA

Chemical Properties

CAS No.: 2117759-07-4


Formula: C18H17NO6

Molecular Weight: 343.33

Appearance: no data available

Storage: store at low temperature

Powder: -20°C for 3 years | In solvent: -80°C for 1 year



Biological Description

Description	3,4-DAA has anti-inflammatory activity, ameliorates acute hepatic allograft injury, and alleviates severe acute pancreatitis by inhibiting intestinal barrier dysfunction and NF-κ activation.3,4-DAA inhibits EOC20 cell-inducible nitric oxide synthase (iNOS) induced by IFN-γ and lipopolysaccharide.		
Targets(IC50)	NOS		
In vitro	3,4-DAA can alleviate the severity of colitis by inhibiting the response of Th1 cells, promoting the expression of Th2 cytokines, and inducing the expression of CD4(+)CD25(+) T cells[1].		
In vivo	3,4-DAA is an orally active synthetic derivative of the tryptophan metabolite anthranilic acid, which can reverse paralysis in mice with experimental autoimmune encephalomyelitis (EAE), a model of multiple sclerosis (MS)[1].		

Solubility Information

Solubility	DMSO: 5 mg/mL (14.56 mM),Sonication is recommended.	
	(< 1 mg/ml refers to the product slightly soluble or insoluble)	

Preparing Stock Solutions

	1mg	5mg	10mg	
1 mM	2.9126 mL	14.5632 mL	29.1265 mL	
5 mM	0.5825 mL	2.9126 mL	5.8253 mL	
10 mM	0.2913 mL	1.4563 mL	2.9126 mL	
50 mM	0.0583 mL	0.2913 mL	0.5825 mL	

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Page 1 of 2 www.targetmol.com

Reference

Quan Wen, et al. N-(3', 4'-dimethoxycinnamonyl) anthranilic acid alleviated experimental colitis by inhibiting autoimmune response and inducing CD4+ CD25+ regulatory T cells production. J Gastroenterol Hepatol. 2013 Aug;



Page 2 of 2 www.targetmol.com